Navigation Links
Dr. Susan Froshauer to join Connecticut bioscience team at CURE

HARTFORD, Conn., Feb. 12, 2013 /PRNewswire/ -- Peter R. Farina , Ph.D. and David W. Keiser , the two co-chairs of CURE (Connecticut United for Research Excellence), the state bioscience organization, today released the following statement about organizational changes at CURE.

After ten years at the helm, Paul Pescatello , the current President and CEO of CURE, has decided to step back from that role so that he can dedicate some additional time to private business ventures and other non-life sciences policy issues. Paul has made great strides for CURE and so we are pleased to report that he has agreed to continue to coordinate our government relations efforts as Chair of the CURE BioScience Growth Council and as a CURE Board and Executive Committee member. This arrangement will allow Paul to bring even greater focus and depth to CURE's life sciences advocacy.

The state has recently increased its investment in the life sciences and in entrepreneurship. For example, it has invited The Jackson Laboratory to develop a genomic medicine facility in Farmington and created Connecticut's Innovation Ecosystem, a public-private partnership, with hubs in Hartford, New Haven, Stamford and Storrs, to support high-value technology-based start-up and stage 2 companies. Furthermore, Governor Malloy has proposed a new $200 million Bioscience Innovation Act and announced a $1.5 million investment in UConn to support STEM (Science, Technology, Engineering and Math) education activities.

CURE seeks to strengthen and enhance its mission to support these efforts. To do so most effectively, and build on Paul's success, it is our great pleasure to announce that a good friend of the Connecticut life sciences community, Dr. Susan Froshauer , has agreed to assume the position of Chief Executive Officer and President of CURE, effective April 1. Susan is well-known to the CURE community and has a wealth of experience that makes her an ideal choice to lead the organization.

Susan is an experienced scientist, mentor, entrepreneur and investor with skill at connecting academic expertise and technology with the commercial sector. She is currently Director of the Technology Exchange Portal at the University of Connecticut's Office of Economic Development.  In this role Susan assists Connecticut-based entrepreneurs and organizations with initiatives that train students, create jobs and contribute to economic development. She connects ideas with business expertise, business plans with investors and industry with scholars.

Until 2010, Susan served as President and CEO of Rib-X Pharmaceuticals, which she co-founded in New Haven in 2000. Under her leadership, Rib-X raised more than $160 million in private equity, bridge financing and government grants and built a robust pipeline of antibiotics to treat serious hospital infections. Prior to Rib-X, Susan served as a member of Pfizer's Strategic Alliance Group where she was key to the creation of a $200 million investment portfolio that transformed the Pfizer global research and development strategy, helping the company identify new resources for drug discovery.

Susan received a Ph.D. in Microbiology and Molecular Genetics from Harvard University and a B. A. from Connecticut College. She performed post-doctoral research at Yale Medical School in the Department of Cell Biology as a Jane Coffin Child 's Fellow.

Susan will initially focus on expanding the CURE network, fostering connectivity among members, educators, investors and entrepreneurs, helping to build the bridges necessary to transform cutting edge bioscience research into funded, sustainable start-up biotechs as well as fortifying CURE's commitment to education.

Please join us in welcoming Susan and thanking Paul for his decade of CURE leadership. The combined team of Susan and Paul will strengthen and enhance CURE and its work on behalf of CURE members.

Photo of Paul Pescatello :
Photo of Dr. Susan Froshauer : Froshauer.jpg

Bill Kelly
HarveyMalis Communications LLC

SOURCE CURE (Connecticut United for Research Excellence)
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Connecticut Radiology Group Leverages MedInformatix RIS to Achieve Stage 1 Meaningful Use Objectives
2. Medbox, Inc. Rides a Wave of Local Media Support in Connecticut
3. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
4. Sigma-Aldrich Corporations Sigma Life Science Business to Distribute Worldwide Olink Biosciences Protein Interaction Analysis Technology
5. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
6. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
7. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
8. Amarantus BioScience Secures an Additional $1.4 Million in Financing Commitments
9. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
10. Congresswoman Barbara Lee Visits Tethys Bioscience
11. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
Post Your Comments:
(Date:10/12/2015)... New York , October 12, 2015 ... (FMI) delivers key insights on the global vital signs monitoring ... Devices Market: Global Industry Analysis and Opportunity Assessment 2015-2025." The ... at a healthy CAGR of 9.5% and 9.2% in terms ... to factors, regarding which FMI offers major insights in detail ...
(Date:10/12/2015)... Oct. 12, 2015 Beginning October 1, 2015 ... Partner, the fastest growing practice management system for therapists, ... easily converts all patient diagnostic codes from the former ... --> --> Therapy Partner has ... mental health practitioners to easily understand the conversion to ...
(Date:10/12/2015)... , Oct. 12, 2015 Indivior PLC (LON: INDV) ... of Delaware granted the Company,s motion ... Abbreviated New Drug Application (ANDA) No. 205299 to market a ... and naloxone) Sublingual Film (CIII) in the United ... Since August 2013, Indivior has received Paragraph IV certifications ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... October 12, 2015 , ... To help ... its charitable donation to the National Breast Cancer Foundation. The National Breast Cancer ... breast cancer through early detection, education, and support services. , The annual campaign ...
(Date:10/12/2015)... ... October 12, 2015 , ... SQM Group ... a contact channel benchmarking study. Be a part of this insightful ... for improving customer experience, customer journey, contact channel execution and intelligence, workforce optimization, ...
(Date:10/12/2015)... ... ... Holcomb – Kreithen Plastic Surgery and MedSpa, PLLC (“Holcomb – Kreithen”), one of ... Surgery University,” an educational series of mini seminars covering aesthetic and plastic surgery options, ... Saturday, October 24, 2015. , The goal of the event is to provide hands-on ...
(Date:10/12/2015)... ... October 12, 2015 , ... The Asthma and ... Engagement Award by the Patient-Centered Outcomes Research Institute (PCORI) for a new project ... , The project, entitled “Training Patients with Asthma to Understand and Participate in ...
(Date:10/12/2015)... ... October 12, 2015 , ... International law firm Greenberg ... with the U.S. Biomedical Advanced Research and Development Authority (BARDA) reported to be ... ReCell® Autologous Cell Harvesting Device under a U.S. mass casualty preparedness program. ...
Breaking Medicine News(10 mins):